Publications by authors named "Yohei Yabuki"

Claim this Profile
A
A favorable antitumor efficacy of sotorasib in a patient with G12C-mutated pulmonary large-cell neuroendocrine carcinoma.
Keisuke Nakanishi, Hirokazu Ogino, Kojin Murakami, Yasuyo Saijo, Nobuhito Naito, Yohei Yabuki

Int Cancer Conf J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clock pathway inhibitor overcomes tumor immune-exclusion via regulation of fibrocyte differentiation.
Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, Reona Matsuo, Na Thi Nguyen, Yohei Yabuki

NPJ Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia-inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-γ-induced chemokines in tumor cells.
Yohei Yabuki, Atsushi Mitsuhashi, Hirokazu Ogino, Aito Yoshida, Na Thi Nguyen

Int J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor-associated paraneoplastic cerebellar degeneration in a case of extensive-stage small-cell lung cancer with pre-existing anti-SOX1 antibody.
Kaori Nii, Hirokazu Ogino, Hiroki Bando, Yuki Yamamoto, Koji Fujita, Yohei Yabuki

J Med Invest· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer.
Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yohei Yabuki

Int J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformation of mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review.
Kenya Miyamoto, Hirokazu Ogino, Takumi Kakimoto, Yugo Matsumura, Keiko Haji, Yohei Yabuki

Respir Med Case Rep· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki

Thorac Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.
Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu

Thorac Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FoundationOne CDx detected an uncovered variant of exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma.
Hiroki Takahashi, Hirokazu Ogino, Hiroki Bando, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki

Respir Med Case Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.
Seiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, Keiko Haji, Kozo Kagawa, Yohei Yabuki

Respir Med Case Rep· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.
Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki

Thorac Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, Kensuke Kondo, Ei Ogawa, Yohei Yabuki

BMC Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab.
Masahiro Sako, Hiroshi Nokihara, Kensuke Kondo, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki

Thorac Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.
Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki

BMC Pulm Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis